Molecular imaging of atherosclerosis: spotlight on Raman spectroscopy and surface-enhanced Raman scattering

Neil MacRitchie, Gianluca Grassia, Jonathan Noonan, Paul Garside, Duncan Graham, Pasquale Maffia

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

To accurately predict atherosclerotic plaque progression, a detailed phenotype of the lesion at the molecular level is required. Here, we assess the respective merits and limitations of molecular imaging tools. Clinical imaging includes contrast-enhanced ultrasound (CEUS), an inexpensive and non-toxic technique but with poor sensitivity. Computed tomography (CT) benefits from high spatial resolution but poor sensitivity coupled with an increasing radiation burden that limits multiplexing. Despite high sensitivity, positron emission tomography (PET) and single-photon emission tomography (SPECT) have disadvantages when applied to multiplex molecular imaging due to poor spatial resolution, signal cross talk and increasing radiation dose. In contrast, magnetic resonance imaging (MRI) is non-toxic, displays good spatial resolution but poor sensitivity. Pre-clinical techniques include near-infrared fluorescence (NIRF), which provides good spatial resolution and sensitivity; however, multiplexing with NIRF is limited, due to photobleaching and spectral overlap. Fourier transform infrared spectroscopy (FT-IR) and Raman spectroscopy are label-free techniques that detect molecules based on the vibrations of chemical bonds. Both techniques offer fast acquisition times with Raman showing superior spatial resolution. Raman signals are inherently weak; however, leading to the development of surface-enhanced Raman spectroscopy (SERS) that offers greatly increased sensitivity due to utilising metallic nanoparticles that can be functionalised with biomolecules targeted against plaque ligands while offering high multiplexing potential. This asset combined with high spatial resolution makes SERS an exciting prospect as a diagnostic tool. The ongoing refinements of SERS technologies such as deep tissue imaging and portable systems making SERS a realistic prospect for translation to the clinic.
LanguageEnglish
Pages460-467
Number of pages8
JournalHeart
Volume104
Early online date23 Oct 2017
DOIs
Publication statusE-pub ahead of print - 23 Oct 2017

Fingerprint

Molecular Imaging
Raman Spectrum Analysis
Atherosclerosis
Fluorescence
Tomography
Metal Nanoparticles
Radiation
Photobleaching
Atherosclerotic Plaques
Fourier Transform Infrared Spectroscopy
Vibration
Single-Photon Emission-Computed Tomography
Photons
Positron-Emission Tomography
Magnetic Resonance Imaging
Ligands
Technology
Phenotype

Keywords

  • atherosclerosis
  • coronary artery disease
  • molecular imaging
  • Raman
  • surface-enhanced Raman spectroscopy

Cite this

MacRitchie, Neil ; Grassia, Gianluca ; Noonan, Jonathan ; Garside, Paul ; Graham, Duncan ; Maffia, Pasquale. / Molecular imaging of atherosclerosis : spotlight on Raman spectroscopy and surface-enhanced Raman scattering. In: Heart . 2017 ; Vol. 104. pp. 460-467.
@article{c4d61e72e015440ab70faa7f453323e3,
title = "Molecular imaging of atherosclerosis: spotlight on Raman spectroscopy and surface-enhanced Raman scattering",
abstract = "To accurately predict atherosclerotic plaque progression, a detailed phenotype of the lesion at the molecular level is required. Here, we assess the respective merits and limitations of molecular imaging tools. Clinical imaging includes contrast-enhanced ultrasound (CEUS), an inexpensive and non-toxic technique but with poor sensitivity. Computed tomography (CT) benefits from high spatial resolution but poor sensitivity coupled with an increasing radiation burden that limits multiplexing. Despite high sensitivity, positron emission tomography (PET) and single-photon emission tomography (SPECT) have disadvantages when applied to multiplex molecular imaging due to poor spatial resolution, signal cross talk and increasing radiation dose. In contrast, magnetic resonance imaging (MRI) is non-toxic, displays good spatial resolution but poor sensitivity. Pre-clinical techniques include near-infrared fluorescence (NIRF), which provides good spatial resolution and sensitivity; however, multiplexing with NIRF is limited, due to photobleaching and spectral overlap. Fourier transform infrared spectroscopy (FT-IR) and Raman spectroscopy are label-free techniques that detect molecules based on the vibrations of chemical bonds. Both techniques offer fast acquisition times with Raman showing superior spatial resolution. Raman signals are inherently weak; however, leading to the development of surface-enhanced Raman spectroscopy (SERS) that offers greatly increased sensitivity due to utilising metallic nanoparticles that can be functionalised with biomolecules targeted against plaque ligands while offering high multiplexing potential. This asset combined with high spatial resolution makes SERS an exciting prospect as a diagnostic tool. The ongoing refinements of SERS technologies such as deep tissue imaging and portable systems making SERS a realistic prospect for translation to the clinic.",
keywords = "atherosclerosis, coronary artery disease, molecular imaging, Raman, surface-enhanced Raman spectroscopy",
author = "Neil MacRitchie and Gianluca Grassia and Jonathan Noonan and Paul Garside and Duncan Graham and Pasquale Maffia",
year = "2017",
month = "10",
day = "23",
doi = "10.1136/heartjnl-2017-311447",
language = "English",
volume = "104",
pages = "460--467",
journal = "Heart",
issn = "1355-6037",

}

Molecular imaging of atherosclerosis : spotlight on Raman spectroscopy and surface-enhanced Raman scattering. / MacRitchie, Neil; Grassia, Gianluca; Noonan, Jonathan; Garside, Paul; Graham, Duncan; Maffia, Pasquale.

In: Heart , Vol. 104, 23.10.2017, p. 460-467.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Molecular imaging of atherosclerosis

T2 - Heart

AU - MacRitchie, Neil

AU - Grassia, Gianluca

AU - Noonan, Jonathan

AU - Garside, Paul

AU - Graham, Duncan

AU - Maffia, Pasquale

PY - 2017/10/23

Y1 - 2017/10/23

N2 - To accurately predict atherosclerotic plaque progression, a detailed phenotype of the lesion at the molecular level is required. Here, we assess the respective merits and limitations of molecular imaging tools. Clinical imaging includes contrast-enhanced ultrasound (CEUS), an inexpensive and non-toxic technique but with poor sensitivity. Computed tomography (CT) benefits from high spatial resolution but poor sensitivity coupled with an increasing radiation burden that limits multiplexing. Despite high sensitivity, positron emission tomography (PET) and single-photon emission tomography (SPECT) have disadvantages when applied to multiplex molecular imaging due to poor spatial resolution, signal cross talk and increasing radiation dose. In contrast, magnetic resonance imaging (MRI) is non-toxic, displays good spatial resolution but poor sensitivity. Pre-clinical techniques include near-infrared fluorescence (NIRF), which provides good spatial resolution and sensitivity; however, multiplexing with NIRF is limited, due to photobleaching and spectral overlap. Fourier transform infrared spectroscopy (FT-IR) and Raman spectroscopy are label-free techniques that detect molecules based on the vibrations of chemical bonds. Both techniques offer fast acquisition times with Raman showing superior spatial resolution. Raman signals are inherently weak; however, leading to the development of surface-enhanced Raman spectroscopy (SERS) that offers greatly increased sensitivity due to utilising metallic nanoparticles that can be functionalised with biomolecules targeted against plaque ligands while offering high multiplexing potential. This asset combined with high spatial resolution makes SERS an exciting prospect as a diagnostic tool. The ongoing refinements of SERS technologies such as deep tissue imaging and portable systems making SERS a realistic prospect for translation to the clinic.

AB - To accurately predict atherosclerotic plaque progression, a detailed phenotype of the lesion at the molecular level is required. Here, we assess the respective merits and limitations of molecular imaging tools. Clinical imaging includes contrast-enhanced ultrasound (CEUS), an inexpensive and non-toxic technique but with poor sensitivity. Computed tomography (CT) benefits from high spatial resolution but poor sensitivity coupled with an increasing radiation burden that limits multiplexing. Despite high sensitivity, positron emission tomography (PET) and single-photon emission tomography (SPECT) have disadvantages when applied to multiplex molecular imaging due to poor spatial resolution, signal cross talk and increasing radiation dose. In contrast, magnetic resonance imaging (MRI) is non-toxic, displays good spatial resolution but poor sensitivity. Pre-clinical techniques include near-infrared fluorescence (NIRF), which provides good spatial resolution and sensitivity; however, multiplexing with NIRF is limited, due to photobleaching and spectral overlap. Fourier transform infrared spectroscopy (FT-IR) and Raman spectroscopy are label-free techniques that detect molecules based on the vibrations of chemical bonds. Both techniques offer fast acquisition times with Raman showing superior spatial resolution. Raman signals are inherently weak; however, leading to the development of surface-enhanced Raman spectroscopy (SERS) that offers greatly increased sensitivity due to utilising metallic nanoparticles that can be functionalised with biomolecules targeted against plaque ligands while offering high multiplexing potential. This asset combined with high spatial resolution makes SERS an exciting prospect as a diagnostic tool. The ongoing refinements of SERS technologies such as deep tissue imaging and portable systems making SERS a realistic prospect for translation to the clinic.

KW - atherosclerosis

KW - coronary artery disease

KW - molecular imaging

KW - Raman

KW - surface-enhanced Raman spectroscopy

UR - http://heart.bmj.com/

U2 - 10.1136/heartjnl-2017-311447

DO - 10.1136/heartjnl-2017-311447

M3 - Article

VL - 104

SP - 460

EP - 467

JO - Heart

JF - Heart

SN - 1355-6037

ER -